3se3 › Citations

Structural linkage between ligand discrimination and receptor activation by type I interferons.

Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, Nolan GP, Piehler J, Schreiber G, Garcia KC
Cell 146 621-32 (2011)
Related entries: 3s8w, 3s98, 3s9d, 3se4

Cited: 217 times
EuropePMC logo PMID: 21854986

Abstract

Type I Interferons (IFNs) are important cytokines for innate immunity against viruses and cancer. Sixteen human type I IFN variants signal through the same cell-surface receptors, IFNAR1 and IFNAR2, yet they can evoke markedly different physiological effects. The crystal structures of two human type I IFN ternary signaling complexes containing IFNα2 and IFNω reveal recognition modes and heterotrimeric architectures that are unique among the cytokine receptor superfamily but conserved between different type I IFNs. Receptor-ligand cross-reactivity is enabled by conserved receptor-ligand "anchor points" interspersed among ligand-specific interactions that "tune" the relative IFN-binding affinities, in an apparent extracellular "ligand proofreading" mechanism that modulates biological activity. Functional differences between IFNs are linked to their respective receptor recognition chemistries, in concert with a ligand-induced conformational change in IFNAR1, that collectively control signal initiation and complex stability, ultimately regulating differential STAT phosphorylation profiles, receptor internalization rates, and downstream gene expression patterns.

Reviews - 3se3 mentioned but not cited (8)

  1. A Review of the Microbial Production of Bioactive Natural Products and Biologics. Pham JV, Yilma MA, Feliz A, Majid MT, Maffetone N, Walker JR, Kim E, Cho HJ, Reynolds JM, Song MC, Park SR, Yoon YJ. Front Microbiol 10 1404 (2019)
  2. The molecular basis for differential type I interferon signaling. Schreiber G. J Biol Chem 292 7285-7294 (2017)
  3. Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes. Ng CT, Mendoza JL, Garcia KC, Oldstone MB. Cell 164 349-352 (2016)
  4. Subversion of cytokine networks by virally encoded decoy receptors. Epperson ML, Lee CA, Fremont DH. Immunol Rev 250 199-215 (2012)
  5. IFN-λ: A new spotlight in innate immunity against influenza virus infection. Sun Y, Jiang J, Tien P, Liu W, Li J. Protein Cell 9 832-837 (2018)
  6. Interferon-Inducible Myxovirus Resistance Proteins: Potential Biomarkers for Differentiating Viral from Bacterial Infections. Zav'yalov VP, Hämäläinen-Laanaya H, Korpela TK, Wahlroos T. Clin Chem 65 739-750 (2019)
  7. The JAK-STAT pathway: from structural biology to cytokine engineering. Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, Zhang J, Mi P, Kobe B, Wang F. Signal Transduct Target Ther 9 221 (2024)
  8. IFNα Subtypes in HIV Infection and Immunity. Karakoese Z, Ingola M, Sitek B, Dittmer U, Sutter K. Viruses 16 364 (2024)

Articles - 3se3 mentioned but not cited (14)



Reviews citing this publication (73)

  1. Shared and Distinct Functions of Type I and Type III Interferons. Lazear HM, Schoggins JW, Diamond MS. Immunity 50 907-923 (2019)
  2. The molecular details of cytokine signaling via the JAK/STAT pathway. Morris R, Kershaw NJ, Babon JJ. Protein Sci 27 1984-2009 (2018)
  3. The Dual Nature of Type I and Type II Interferons. Lee AJ, Ashkar AA. Front Immunol 9 2061 (2018)
  4. JAK/STAT signaling in hematological malignancies. Vainchenker W, Constantinescu SN. Oncogene 32 2601-2613 (2013)
  5. Regulation of antiviral T cell responses by type I interferons. Crouse J, Kalinke U, Oxenius A. Nat Rev Immunol 15 231-242 (2015)
  6. Decoding type I and III interferon signalling during viral infection. Mesev EV, LeDesma RA, Ploss A. Nat Microbiol 4 914-924 (2019)
  7. The interferons and their receptors--distribution and regulation. de Weerd NA, Nguyen T. Immunol Cell Biol 90 483-491 (2012)
  8. Interferons and viruses: an evolutionary arms race of molecular interactions. Hoffmann HH, Schneider WM, Rice CM. Trends Immunol 36 124-138 (2015)
  9. Interferon target-gene expression and epigenomic signatures in health and disease. Barrat FJ, Crow MK, Ivashkiv LB. Nat Immunol 20 1574-1583 (2019)
  10. Insights into cytokine-receptor interactions from cytokine engineering. Spangler JB, Moraga I, Mendoza JL, Garcia KC. Annu Rev Immunol 33 139-167 (2015)
  11. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Piehler J, Thomas C, Garcia KC, Schreiber G. Immunol Rev 250 317-334 (2012)
  12. Interferons and their stimulated genes in the tumor microenvironment. Cheon H, Borden EC, Stark GR. Semin Oncol 41 156-173 (2014)
  13. Type I interferons in viral control and immune regulation. Teijaro JR. Curr Opin Virol 16 31-40 (2016)
  14. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. Davidson S, Maini MK, Wack A. J Interferon Cytokine Res 35 252-264 (2015)
  15. The molecular basis for functional plasticity in type I interferon signaling. Schreiber G, Piehler J. Trends Immunol 36 139-149 (2015)
  16. Type I Interferons as Regulators of Lung Inflammation. Makris S, Paulsen M, Johansson C. Front Immunol 8 259 (2017)
  17. Evolution of Interferons and Interferon Receptors. Secombes CJ, Zou J. Front Immunol 8 209 (2017)
  18. Inborn errors of anti-viral interferon immunity in humans. Sancho-Shimizu V, Perez de Diego R, Jouanguy E, Zhang SY, Casanova JL. Curr Opin Virol 1 487-496 (2011)
  19. The yin and yang of viruses and interferons. Wang BX, Fish EN. Trends Immunol 33 190-197 (2012)
  20. Fine tuning type I interferon responses. Hertzog PJ, Williams BR, Williams BR. Cytokine Growth Factor Rev 24 217-225 (2013)
  21. The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Walter MR. Curr Top Microbiol Immunol 380 191-212 (2014)
  22. Interferons in the central nervous system: a few instruments play many tunes. Owens T, Khorooshi R, Wlodarczyk A, Asgari N. Glia 62 339-355 (2014)
  23. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Schreiber G. Front Immunol 11 595739 (2020)
  24. Message in a bottle: small signalling peptide outputs during growth and development. Czyzewicz N, Yue K, Beeckman T, De Smet I. J Exp Bot 64 5281-5296 (2013)
  25. The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases. López de Padilla CM, Niewold TB. Gene 576 14-21 (2016)
  26. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. Fuchs SY. J Interferon Cytokine Res 33 211-225 (2013)
  27. Type I interferon signaling, regulation and gene stimulation in chronic virus infection. Lukhele S, Boukhaled GM, Brooks DG. Semin Immunol 43 101277 (2019)
  28. The Role of Structure in the Biology of Interferon Signaling. Walter MR. Front Immunol 11 606489 (2020)
  29. Type III IFNs: Beyond antiviral protection. Kotenko SV, Rivera A, Parker D, Durbin JE. Semin Immunol 43 101303 (2019)
  30. Interferon lambda: a new sword in cancer immunotherapy. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Clin Dev Immunol 2011 349575 (2011)
  31. Understanding cytokine and growth factor receptor activation mechanisms. Atanasova M, Whitty A. Crit Rev Biochem Mol Biol 47 502-530 (2012)
  32. Emerging principles of cytokine pharmacology and therapeutics. Saxton RA, Glassman CR, Garcia KC. Nat Rev Drug Discov 22 21-37 (2023)
  33. How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. Reder AT, Feng X. J Interferon Cytokine Res 34 589-599 (2014)
  34. Interferon gamma receptor: the beginning of the journey. Blouin CM, Lamaze C. Front Immunol 4 267 (2013)
  35. Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures. Felix J, Savvides SN. Nat Rev Immunol 17 112-129 (2017)
  36. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Zheng X, Wu Y, Bi J, Huang Y, Cheng Y, Li Y, Wu Y, Cao G, Tian Z. Cell Mol Immunol 19 192-209 (2022)
  37. Viral pathogen-induced mechanisms to antagonize mammalian interferon (IFN) signaling pathway. Rojas JM, Alejo A, Martín V, Sevilla N. Cell Mol Life Sci 78 1423-1444 (2021)
  38. Interferon Receptor Trafficking and Signaling: Journey to the Cross Roads. Zanin N, Viaris de Lesegno C, Lamaze C, Blouin CM. Front Immunol 11 615603 (2020)
  39. Multifarious determinants of cytokine receptor signaling specificity. Moraga I, Spangler J, Mendoza JL, Garcia KC. Adv Immunol 121 1-39 (2014)
  40. Innate immune responses of salmonid fish to viral infections. Collet B. Dev Comp Immunol 43 160-173 (2014)
  41. The Role of Type I IFNs in Influenza: Antiviral Superheroes or Immunopathogenic Villains? Wu W, Metcalf JP. J Innate Immun 12 437-447 (2020)
  42. IFNA2: The prototypic human alpha interferon. Paul F, Pellegrini S, Uzé G. Gene 567 132-137 (2015)
  43. Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Newby BN, Mathews CE. Front Endocrinol (Lausanne) 8 232 (2017)
  44. Erythropoietin regulation of red blood cell production: from bench to bedside and back. Bhoopalan SV, Huang LJ, Weiss MJ. F1000Res 9 F1000 Faculty Rev-1153 (2020)
  45. Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Tomasello E, Pollet E, Vu Manh TP, Uzé G, Dalod M. Front Immunol 5 526 (2014)
  46. Type I interferon in neurological disease-the devil from within. Hofer MJ, Campbell IL. Cytokine Growth Factor Rev 24 257-267 (2013)
  47. ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. Zuo C, Sheng X, Ma M, Xia M, Ouyang L. Oncotarget 7 74393-74409 (2016)
  48. Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity. Eshleman EM, Lenz LL. Front Immunol 5 431 (2014)
  49. Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes. Wittling MC, Cahalan SR, Levenson EA, Rabin RL. Front Immunol 11 605673 (2020)
  50. Differential effects of type I and II interferons on myeloid cells and resistance to intracellular bacterial infections. Kearney S, Delgado C, Lenz LL. Immunol Res 55 187-200 (2013)
  51. Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes. Padariya M, Sznarkowska A, Kote S, Gómez-Herranz M, Mikac S, Pilch M, Alfaro J, Fahraeus R, Hupp T, Kalathiya U. Biomolecules 11 622 (2021)
  52. Immunoinflammatory diseases of the central nervous system - the tale of two cytokines. Hofer MJ, Campbell IL. Br J Pharmacol 173 716-728 (2016)
  53. Pleiotropic Roles of Type 1 Interferons in Antiviral Immune Responses. Teijaro JR. Adv Immunol 132 135-158 (2016)
  54. The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. Musella M, Galassi C, Manduca N, Sistigu A. Biology (Basel) 10 856 (2021)
  55. Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease. Fox LE, Locke MC, Lenschow DJ. Front Immunol 11 606874 (2020)
  56. Potential role of IFN-α in COVID-19 patients and its underlying treatment options. Yang L, Wang J, Hui P, Yarovinsky TO, Badeti S, Pham K, Liu C. Appl Microbiol Biotechnol 105 4005-4015 (2021)
  57. Type 1 Interferon in the Human Intestine-A Co-ordinator of the Immune Response to the Microbiota. Giles EM, Stagg AJ. Inflamm Bowel Dis 23 524-533 (2017)
  58. Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C. Scagnolari C, Antonelli G. Expert Opin Biol Ther 13 693-711 (2013)
  59. Detection of intermolecular NOE interactions in large protein complexes. Anglister J, Srivastava G, Naider F. Prog Nucl Magn Reson Spectrosc 97 40-56 (2016)
  60. Type I interferons in regulation of mucosal immunity. Mangan NE, Fung KY. Immunol Cell Biol 90 510-519 (2012)
  61. Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow. Xiong F, Wang Q, Wu GH, Liu WZ, Wang B, Chen YJ. Biomark Res 10 69 (2022)
  62. Porcine Interferon Complex and Co-Evolution with Increasing Viral Pressure after Domestication. Jennings J, Sang Y. Viruses 11 E555 (2019)
  63. Lung disease manifestations in Down syndrome. Danopoulos S, Deutsch GH, Dumortier C, Mariani TJ, Al Alam D. Am J Physiol Lung Cell Mol Physiol 321 L892-L899 (2021)
  64. The role of a non-canonical JAK-STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis: An example of Occam's Broom? Ahmed CM, Johnson HM. JAKSTAT 2 e26227 (2013)
  65. High efficiency targeting of IFN-α activity: possible applications in fighting tumours and infections. Uzé G, Tavernier J. Cytokine Growth Factor Rev 26 179-182 (2015)
  66. Mapping Determinants of Cytokine Signaling via Protein Engineering. Gorby C, Martinez-Fabregas J, Wilmes S, Moraga I. Front Immunol 9 2143 (2018)
  67. Molecular and cellular factors determining the functional pleiotropy of cytokines. McFarlane A, Pohler E, Moraga I. FEBS J 290 2525-2552 (2023)
  68. System-Based Approaches to Delineate the Antiviral Innate Immune Landscape. Krey K, Babnis AW, Pichlmair A. Viruses 12 E1196 (2020)
  69. Breaching the Bacterial Envelope: The Pivotal Role of Perforin-2 (MPEG1) Within Phagocytes. Merselis LC, Rivas ZP, Munson GP. Front Immunol 12 597951 (2021)
  70. Alternative strategies for Chlamydia treatment: Promising non-antibiotic approaches. Hou C, Jin Y, Wu H, Li P, Liu L, Zheng K, Wang C. Front Microbiol 13 987662 (2022)
  71. Type I interferon pathway genetic variants in severe COVID-19. Montenegro AFL, Clementino MAF, Yaochite JNU. Virus Res 342 199339 (2024)
  72. Structure-function of type I and III interferons. de Weerd NA, Kurowska AK, Mendoza JL, Schreiber G. Curr Opin Immunol 86 102413 (2024)
  73. The Innate Immune Response in DENV- and CHIKV-Infected Placentas and the Consequences for the Fetuses: A Minireview. de Andrade Vieira Alves F, Nunes PCG, Arruda LV, Salomão NG, Rabelo K. Viruses 15 1885 (2023)

Articles citing this publication (122)



Quick links